Literature DB >> 10907384

The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial.

D A Froehling1, J M Bowen, D N Mohr, R H Brey, C W Beatty, P C Wollan, M D Silverstein.   

Abstract

OBJECTIVE: To compare the canalith repositioning procedure (CRP) with a sham maneuver for the treatment of benign paroxysmal positional vertigo. PATIENTS AND METHODS: We recruited 50 patients with a history of positional vertigo and unilateral positional nystagmus on physical examination (Dix-Hallpike maneuver). Patients were randomized to either the CRP (n = 24) or a sham maneuver (n = 26). Measured outcomes included resolution of vertigo and positional nystagmus at follow-up examination.
RESULTS: The mean duration of follow-up was 10 days for both groups. Resolution of symptoms was reported by 12 (50%) of the 24 patients in the CRP group and by 5 (19%) of the 26 patients in the sham group (P = .02). The results of the Dix-Hallpike maneuver were negative for positional nystagmus in 16 (67%) of 24 patients in the CRP group and in 10 (38%) of 26 patients in the sham group (P = .046).
CONCLUSION: The CRP is effective treatment of benign paroxysmal positional vertigo, and this procedure can be performed by general internists on outpatients with this disorder.

Entities:  

Mesh:

Year:  2000        PMID: 10907384     DOI: 10.4065/75.7.695

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  21 in total

Review 1.  Benign paroxysmal positional vertigo.

Authors:  R J Tusa
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  Effectiveness of the Epley manoeuvre in posterior canal benign paroxysmal positional vertigo: a randomised clinical trial in primary care.

Authors:  José Luis Ballvé; Ricard Carrillo-Muñoz; Yolanda Rando-Matos; Iván Villar; Oriol Cunillera; Jesús Almeda; Estrella Rodero; Xavier Monteverde; Carles Rubio; Noemí Moreno; Olga Lucia Arias; Carlos Martin; Rafael Azagra
Journal:  Br J Gen Pract       Date:  2018-12-03       Impact factor: 5.386

3.  Canalith repositioning variations for benign paroxysmal positional vertigo.

Authors:  Helen S Cohen; Haleh Sangi-Haghpeykar
Journal:  Otolaryngol Head Neck Surg       Date:  2010-09       Impact factor: 3.497

4.  Short-term efficacy of Epley's manoeuvre: a double-blind randomised trial.

Authors:  M von Brevern; T Seelig; A Radtke; K Tiel-Wilck; H Neuhauser; T Lempert
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

5.  Repositioning chairs in benign paroxysmal positional vertigo: implications and clinical outcome.

Authors:  Niels West; Søren Hansen; Martin Nue Møller; Sune Land Bloch; Mads Klokker
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-07       Impact factor: 2.503

6.  Natural history of horizontal canal benign paroxysmal positional vertigo is truly short.

Authors:  Dae Bo Shim; Kyung Min Ko; Joon Hee Lee; Hong Ju Park; Mee Hyun Song
Journal:  J Neurol       Date:  2014-10-11       Impact factor: 4.849

7.  Comparative Study of Management of BPPV (Benign Paroxysmal Positional Vertigo) with only Drugs Versus Drugs Plus Epley Manoeuvre.

Authors:  Achyuth Panuganti; Sudarshan Reddy Loka; Shankar Tati; Amreeta Kaur Punga
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-02

8.  Long-term outcome and health-related quality of life in benign paroxysmal positional vertigo.

Authors:  Jose A Lopez-Escamez; Maria J Gamiz; Antonio Fernandez-Perez; Manuel Gomez-Fiñana
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-11-16       Impact factor: 2.503

Review 9.  Evidence-based practice: management of vertigo.

Authors:  Anh T Nguyen-Huynh
Journal:  Otolaryngol Clin North Am       Date:  2012-10       Impact factor: 3.346

10.  A mouse model for benign paroxysmal positional vertigo with genetic predisposition for displaced otoconia.

Authors:  Amiel A Dror; Shahar Taiber; Eyal Sela; Ophir Handzel; Karen B Avraham
Journal:  Genes Brain Behav       Date:  2020-01-16       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.